10 Small Cap Stocks with Potential to Rise 1000 Percent
Small-cap stocks have returned to the market’s risk conversation in 2026.
Olema Pharmaceuticals Inc. (OLMA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Paradigm Biocapital Advisors Senai Asefaw | 8,670,576 | $108,468,906 | +9% | 2.03% |
| 2. | Biotechnology Value Fund / BVF Inc Mark Lampert | 5,295,893 | $66,251,621 | 1.69% | |
| 3. | Siren L.L.C. Raymond Debbane | 4,856,949 | $60,760,432 | +3% | 1.23% |
| 4. | Logos Capital Arsani William | 3,208,875 | $40,143,026 | 1.73% | |
| 5. | Cormorant Asset Management Bihua Chen | 2,150,000 | $26,896,500 | -45% | 1.38% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.76 | 300,000 | $1,727,370.00 | 7,800,000 | 2025-01-08 | Filing | |
| $6.75 | 700,761 | $4,730,136.75 | 700,761 | 2024-12-13 | Filing | |
| $6.75 | 700,761 | $4,730,136.75 | 1,408,875 | 2024-12-17 | Filing | |
| $13.09 | 50,000 | $654,250.00 | 1,800,000 | 2023-12-05 | Filing | |
| $14.95 | 50,000 | $747,480.00 | 1,750,000 | 2023-12-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.71 | 12,500 | $146,425.00 | 702,770 | 2026-07-24 | Filing | |
| $11.58 | 12,500 | $144,737.50 | 715,270 | 2026-07-23 | Filing | |
| $24.69 | 233 | $5,752.77 | 0 | 2026-03-04 | Filing | |
| $24.25 | 24,767 | $600,599.75 | 233 | 2026-03-04 | Filing | |
| $23.01 | 15,000 | $345,150.00 | 0 | 2026-03-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 12,143,062 | $151,909,702 | 0.01% | |
| 2. | 7,094,413 | $88,802,842 | 0.04% | |
| 3. | 7,085,249 | $88,636,465 | 5.27% | |
| 4. | 6,714,691 | $84,000,783 | 0% | |
| 5. | 4,316,058 | $53,993,886 | 0% |
News See All
Citi, Stifel Bullish on Olema (OLMA) Despite COO Departure
Olema Pharmaceuticals Inc. (NASDAQ:OLMA) is one of 15 stocks with the biggest hedge fund momentum, after gaining 28 hedge fund holders during the fourth quarter of 2025.
15 Stocks with the Biggest Hedge Fund Momentum
On February 23, Bloomberg News reported that during the week ended February 19, hedge funds registered record-high net sales of global stocks, the highest since early April 2025.
Stifel Initiates Coverage on Olema Pharmaceuticals (OLMA) With Buy Rating
On February 11, Laura Prendergast of Stifel Nicolaus initiated coverage of Olema Pharmaceuticals (NASDAQ:OLMA).
17 Biotechnology Stocks with More Than 50% Upside
2025 was a year characterized by both challenges and opportunities for the biotechnology sector.
10 Best Small-Cap Stocks Ready to Explode in 2026
On January 27, Matt Stucky from Northwestern Mutual appeared on a CNBC Television interview to discuss the performance of small-cap stocks.
Wall Street Remains Bullish on Olema Pharmaceuticals Inc. (OLMA)
The update comes as part of the firm’s assumption of coverage on 22 biotech firms that have a market capitalization between $300 million and $10 billion.
14 Best Booming Stocks to Buy Right Now
In a report released on January 9, Goldman Sachs said that it expects the index to rally 12% in 2026.
Olema (OLMA) Hits 4-Year High as Jefferies Hikes PT
The upgrade reflected the investment firm’s confidence in oral Selective Estrogen Receptor Degrader (SERD), supported by Roche’s encouraging results from the phase 3 trial of giredestrant in the treatment...
Guggenheim Initiates Olema Pharmaceuticals (OLMA) Coverage with Buy Rating and $20 PT, Cites Palazestrant Potential
Olema Pharmaceuticals Inc. (NASDAQ:OLMA) is one of the best hot stocks to invest in. On October 8, Guggenheim initiated coverage of Olema Oncology with a Buy rating and $20 price target.
Hedge Fund Resource Center